Removal of abnormal cells from eye surface

Removal of abnormal cells from surface of eye consent form can be used when treating OSSN (ocular surface squamous neoplasia) and CIN (conjunctival intraepithelial neoplasia). It is written in plain language to make it easier for patients to understand.

We thank OMIC Director Steven I. Rosenfeld, MD, for his assistance in developing this form.

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Six reasons OMIC is the best choice for ophthalmologists in America.

Best at defending claims.

An ophthalmologist pays nearly half a million dollars in premiums over the course of a career. Premium paid is directly related to a carrier’s claims experience. OMIC has a higher win rate taking tough cases to trial, full consent to settle (no hammer) clause, and access to the best experts. OMIC pays 25% less per claim than other carriers. As a result, OMIC has consistently maintained lower base rates than multispecialty carriers in the U.S.